EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy

Lin Mao, Yangjing Ou, Yuchao Zhang, Minghui Wang, Guoqing Dong, Asma Khanniche, Hailong Wang, Zhenchuan Wu, Haibing Zhang, Landian Hu, Xiangyin Kong

Cancer Immunology, Immunotherapy · 17.03.2026 · 75 (4)

DOI: 10.1007/s00262-026-04356-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 17.03.2026. Verfasst von Lin Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. Hauptthemen laut MEDLINE: Dendritic Cells, Receptor-Interacting Protein Serine-Threonine Kinases, Cancer Vaccines, Immunotherapy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Key Research and Development Program of China, the Global Common Challenges Project of the Chinese Academy of Sciences, Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsReceptor-Interacting Protein Serine-Threonine KinasesCancer VaccinesImmunotherapyNeoplasmsAnimalsMiceHumansTumor MicroenvironmentMice, KnockoutT-Lymphocytes, CytotoxicMice, Inbred C57BLCD8-Positive T-LymphocytesFemale

Stichwörter der Autor:innen

DC vaccineRIPK1Tumor immunotherapyTumor microenvironment

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesCancer VaccinesRipk1 protein, mouse

Autor:innen und Institutionen

  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • ANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China.
  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. hbzhang@sinh.ac.cn.
  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. ldhu2013@163.com.
  • ANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China. ldhu2013@163.com.

Förderung

  • the National Key Research and Development Program of China
  • the Global Common Challenges Project of the Chinese Academy of Sciences
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project

Zitieren

APA

Mao, L., Ou, Y., Zhang, Y., Wang, M., Dong, G., Khanniche, A., Wang, H., Wu, Z., Zhang, H., Hu, L., & Kong, X. (2026). RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy. Cancer Immunology, Immunotherapy, 75(4). https://doi.org/10.1007/s00262-026-04356-5

Vancouver

Mao L, Ou Y, Zhang Y, Wang M, Dong G, Khanniche A, et al. RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy. Cancer Immunology, Immunotherapy. 2026;75(4). doi:10.1007/s00262-026-04356-5

BibTeX
@article{Mao2026,
  author = {Mao, Lin and Ou, Yangjing and Zhang, Yuchao and Wang, Minghui and Dong, Guoqing and Khanniche, Asma and Wang, Hailong and Wu, Zhenchuan and Zhang, Haibing and Hu, Landian and Kong, Xiangyin},
  title = {RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {4},
  doi = {10.1007/s00262-026-04356-5}
}
Kostenlos starten →